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Objectives: To investigate whether smoking habits predict response to rituximab (RTX) in rheumatoid arthritis (RA).
Method: We included patients from the CERERRA international cohort receiving the ﬁrst treatment cycle with
available smoking status (n = 2481, smokers n = 528, non-current smokers n = 1953) and at least one follow-up
visit. Outcome measures were change in Disease Activity Score based on 28-joint count (ΔDAS28) and European
League Against Rheumatism (EULAR) good response at 6 months, with non-current smokers as the referent group.
Results: Compared with non-smokers at baseline, smokers were more often rheumatoid factor (RF)/anti-citrullinated
protein antibody (ACPA) positive and males, had shorter disease duration, lower DAS28 and Health Assessment
Questionnaire (HAQ) score, a higher number of prior biological disease-modifying anti-rheumatic drugs, and were
more likely to receive concomitant conventional synthetic disease-modifying anti-rheumatic drug (csDMARDs).
Disease activity had decreased less in smokers at 6 months (ΔDAS28 = 1.5 vs 1.7, p = 0.006), although the difference
was no longer signiﬁcant after correction for baseline DAS28 (p = 0.41). EULAR good response rates did not differ
between smokers and non-smokers overall or stratiﬁed by RF/ACPA status, although smokers had lower good response
rates among seronegative patients (ACPA-negative: 6% vs 14%, RF-negative: 11% vs 18%). Smoking did not predict
good response [odds ratio (OR) = 1.04, 95% conﬁdence interval (CI) = 0.76–1.41], while ACPA, DAS28, HAQ, and
concomitant csDMARDs were signiﬁcant predictors for good response. However, when stratiﬁed by country, smokers
were less likely to achieve good response in Sweden (unadjusted OR = 0.24, 95% CI = 0.07–0.89), and a trend was
seen in the Czech Republic (OR = 0.45, 95% CI = 0.16–1.02).
Conclusion: In this large, observational, multinational RA cohort, smokers starting RTX differed from non-smokers by having
shorter disease duration and lower disease activity, but more previous treatments. The overall results do not support smoking as
an important predictor for response to RTX in patients with RA.
The role of cigarette smoking in rheumatoid arthritis (RA) is
multifaceted. It is a well-established risk factor for the devel-
opment of RA, especially anti-citrullinated protein antibody
(ACPA)-positive RA in genetically susceptible individuals
(1). It has also been associated with increased occurrence of
extra-articular manifestations (2) and with radiographic pro-
gression (3, 4), and it has been identiﬁed as an important
negative predictor of response to anti-rheumatic therapy,
includingmethotrexate and tumour necrosis factor inhibitors
(TNFis) in several studies (4–6). So far, only a few studies
have examined the association between smoking and
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response to non-TNFi biological disease-modifying anti-
rheumatic drugs (bDMARDs) (6, 7).
Rituximab (RTX) is a B-cell depleting agent which acts
through binding to the CD20 molecule on the surface of
B cells, and induces direct signalling of apoptosis, com-
plement activation, and cell-mediated cytotoxicity
(8). It is a chimeric monoclonal antibody and is approved
for the treatment of active RA after the failure of one or
more TNFis. Its efﬁcacy and acceptable safety proﬁle
have been well established, both in randomized controlled
trials and in observational studies (9–13). The approved
dose of RTX consists of two infusions of 1000 mg admi-
nistered with a 2 week interval, although data show that a
lower dose may be equally efﬁcient (14, 15). Some pre-
dictors of response to RTX have been identiﬁed, the
strongest of them being the presence of autoantibodies,
rheumatoid factor (RF), and ACPAs [usually measured
with the anti-cyclic citrullinated peptide (anti-CCP) test]
(13). Regarding the relationship between RTX effective-
ness and smoking, one letter has been published on a
small study group showing strong negative associations
with response, using non-validated criteria (16).
The aim of this large observational study on RA
patients from several European countries was to
assess whether smoking status inﬂuences the clinical
response to RTX, using outcome measures recom-
mended by the European League Against Rheuma-
tism (EULAR)/American College of Rheumatology
(ACR), and with power to stratify into disease sub-
sets and adjust for potential confounders.
Method
Patient population and selection
The European Collaborative Registries for the Evalua-
tion of Rituximab in Rheumatoid Arthritis (CERERRA)
is an investigator-led, industry-supported initiative with
the aim of evaluating the clinical aspects of RTX use in
patients with RA. The following participating European
registries submitted fully anonymized data sets of
patients with a diagnosis of RA who had started treat-
ment with RTX: Czech Republic, Denmark, Finland,
Norway, Portugal, Russia, Slovenia, Sweden, and Swit-
zerland. It was a retrospective observational study, but
the data were collected prospectively. Data were ana-
lysed both stratiﬁed per country and pooled. Ethical
approval for the use of register data from each register
was obtained by local authorities of each country. The
Regional Ethical Review Board in Stockholm approved
the collection and analysis of anonymized data from the
participating registers. Informed consent was obtained
from each patient before inclusion in each register,
according to local regulations.
Patients starting treatment with RTX regardless of dose
(most received 1 g ×2; a smaller percentage received 500mg
× 2) were identiﬁed. The following information was col-
lected at baseline, which was deﬁned as time of ﬁrst RTX
treatment: demographic data (age, gender); RA disease
duration in years (from the time of RA diagnosis); RF
(positive/negative); ACPA (positive/negative); number of
prior conventional synthetic disease-modifying anti-rheu-
matic drugs (csDMARDs), and number of prior
bDMARDs; Disease Activity Score based on 28-joint status
(DAS28) and its components (swollen joint count, tender
joint count, visual analogue scale general health and ery-
throcyte sedimentation rate, the latter except for Danish
patients in whom only C-reactive protein was available);
functional status based on the Health Assessment Question-
naire (HAQ); and concomitant glucocorticoid and
csDMARD use. DAS28 and HAQ as well as information
on concomitant corticosteroid and csDMARD use were
reported at every follow-up visit. Smoking status was
deﬁned as cigarette smokers (current smokers) and non-
smokers (never and ex-smokers). This information was
only collected at RTX start, except for the Swedish study
population, where information about smoking status (at
diagnosis) was available for patients who also participated
in the Epidemiological Investigation of Rheumatoid Arthri-
tis (EIRA) (6).
Patients with available baseline smoking status and at
least one follow-up visit were included in the current analy-
sis. Response to the ﬁrst treatment cycle was assessed.
Patients who were lost to follow-up or patients who started
treatment with RTX very close to the time of the data
pooling and therefore had not yet had a follow-up visit
were excluded. Last observation carried forward (LOCF)
was used to handle missing DAS28 values for patients who
had a follow-up visit but not a DAS28 assessment (i.e.
patients not lost to follow-up).
Statistical analysis
Data were collected longitudinally. Different time-
frames for follow-up were created: 3 (± 1) and 6 (± 1)
months. For duplicate data (patients with two or more
visits within a time-frame) the last observation was
included. We prioritized 6 month over 3 month data,
when available, but when no such data were available,
we used data from the 3 month visit.
Baseline characteristics were compared between smokers
and non-smokers by means of descriptive statistics. The
normality of variables was tested by skewness. Normally
distributed continuous variables are presented as mean ± sd,
while those with a non-normal distribution are presented as
median (interquartile range). Student’s t-test and Mann–
Whitney U-test were used to compare continuous variables,
while the chi–squared test was used for nominal variables.
The level of statistical signiﬁcance was set to 5%.
Three main analyses were performed. First, the effec-
tiveness of RTX during the ﬁrst 6 months after the ﬁrst
treatment cycle was compared between smokers and
non-smokers, with Disease Activity Score (DAS28) as
the main outcome measure, using standard approaches:
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(i) changes in levels on a continuous scale [reduction of
DAS28 from baseline (ΔDAS28)], (ii) the EULAR
response criteria (good, moderate, no), and (iii) the target
of remission (DAS28 < 2.6) or low disease activity
(LDA) (DAS28 ≤ 3.2). For continuous outcomes, the
two groups were compared by the Student’s t-test and by
linear regression with adjustment for baseline imbal-
ances. Adjusted analyses were only conducted when
the crude p value was < 0.05. Fisher’s exact test was
used for nominal outcomes. Separate stratiﬁed analyses
were performed for the RF and anti-CCP-positive and
-negative disease subsets.
Secondly, logistic regression analysis was performed
with EULAR good response at 6 months as the depen-
dent variable and smoking as the independent variable,
for the whole cohort and for each register separately
(sensitivity analysis). Several other known or potential
predictors of response to RTX (see Table 4) were tested
using univariate logistic regression and then in multi-
variate analysis models. By means of stepwise backward
selection, each of these covariates was excluded from
the model until only statistically signiﬁcant variables
remained. RF and ACPA were included separately in
the model because of strong collinearity between them.
Thirdly, the number of follow-up visits was not the same
for all patients, and the time interval between visits was not
the same for all patients and even for the same patient, as
expected in a real-life setting. For these reasons, mixed-
models analyseswere also performed;mixed-model analysis
is a preferable method for analysing such longitudinal data,
as it can handle uneven spacing of repeated measurements
and evenmissing data (as long asmissing data aremissing at
random). A mixed-effects model with ΔDAS28 as the
dependent variable and baseline smoking status as the ﬁxed
effect was performed to assess the effectiveness of treatment
according to smoking. Time was also ﬁtted in the model as
1/time. The interaction smoking * (1/time) was also included
in themodel. Country and patientwere included in themodel
as random variables. In a second step, several potential
confounders [age, gender, disease duration, number of
prior bDMARDs, concomitant csDMARDs, baseline
DAS28 and HAQ, RF, and ACPA (the last two separately)]
were included in the models. Different association models
for the covariance structure between the repeated measures
of the primary outcomes were performed and compared
using the Akaike information criterion. Smoking groups
were also compared by estimated marginal means.
Results
More than 5000 patients were included in the CERERRA
cohort until the year 2014 and they served as the basis for
the current analyses. After exclusion of patients without
smoking status or with only a baseline visit, 2481 patients
were included in the analyses, of whom 1953 were identi-
ﬁed as non-smokers (never or ex-smokers) and 528 as
smokers (current). Signiﬁcant heterogeneity across coun-
tries was observed regarding the proportion of smokers and
other characteristics (Supplementary Tables S1 and S2).
Baseline characteristics of patients stratiﬁed for smoking
status are summarized in Table 1. Smokers were more
often male, and had shorter disease duration, lower disease
activity, lower functional impairment, a higher number of
previous bDMARDs, and more often concomitant
csDMARD treatment compared to non-smokers.
Effectiveness of RTX according to smoking status
At 6 months’ follow-up, non-smokers had a signiﬁcantly
larger DAS28 reduction from baseline (Table 2). However,
this was not signiﬁcant after correction for baseline DAS28
Table 1. Comparison of baseline demographic, disease, and treatment characteristics for rituximab-treated rheumatoid arthritis
patients in non-smokers versus smokers.
Characteristic
Non-smokers
(N = 1953)
Smokers
(N = 528)
Difference between groups
(p)
Age (years), mean ± sd 52.7 ± 13.1 [1949] 52.6 ± 11.7 [528] 0.99
Gender, % female 85.9 [1953] 62.5 [528] < 0.0001
Disease duration (years), median (IQR) 10.0 (5.0–16.0) [1918] 7.4 (3.9–13.0) [518] < 0.0001
RF, % positive 79.9 [1819] 84.8 [514] 0.01
ACPA, % positive 79.4 [957] 84.6 [325] 0.04
Baseline DAS28, mean ± sd 5.7 ± 1.5 [1855] 5.2 ± 1.6 [489] < 0.0001
Baseline HAQ, mean ± sd 1.6 ± 0.7 [1558] 1.4 ± 0.7 [395] < 0.0001
No. of prior csDMARDs, mean ± sd) 2.6 ± 1.5 [1882] 2.4 ± 1.4 [496] 0.12
No. of prior bDMARDs, median (IQR) 1.0 (0–1.0) [1953] 1.0 (0–2.0) [528] < 0.0001
Concomitant GCs 61.1 [1886] 58.3 [496] 0.25
Dose (mg), median (IQR) 7.5 (5.0–10.0) [1046] 7.5 (5.0–10.0) [231) 0.72
Concomitant csDMARDs 80.0 [1953] 84.8 [528] 0.01
The numbers in square brackets represent the total number of patients with available information.
IQR, interquartile range; RF, rheumatoid factor; ACPA, anti-citrullinated peptide antibodies; DAS28, Disease Activity Score based on
28 joint count and four variables; HAQ, Health Assessment Questionnaire; csDMARDs, conventional synthetic disease-modifying
anti-rheumatic drugs; bDMARDs, biological disease-modifying anti-rheumatic drugs; GCs, glucocorticoids.
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in the regression analysis (Table 2). In addition, no signiﬁ-
cant differences in EULAR response or remission rate were
observed overall between smokers and non-smokers
(Table 2).
After stratiﬁcation for RF and ACPA status (Table 3), no
signiﬁcant differences in response to RTX between smokers
and non-smokers were observed, apart from a signiﬁcantly
higher percentage of patients achieving remission/LDA in
smokers compared to non-smokers among RF-positive
patients (30.6%vs 24.8%, p = 0.04). However, some numer-
ical differences were observed, for example a higher
EULAR good response rate and a higher remission/LDA
rate in non-smokers than in smokers among ACPA-positive
(p = 0.53 and p = 0.22) and ACPA-negative patients
(p = 0.52 and p = 0.51).
Predictors of response
In the univariate logistic regression analysis (Table 4),
smoking status was not predictive for EULAR good
response to RTX after 6 months [unadjusted odds ratio
(OR) = 1.04, 95% conﬁdence interval (CI) 0.76–1.41].
However, because of the heterogeneity between the patient
populations included from the participating countries (Sup-
plementary Table S2), we conducted a sensitivity analysis
stratiﬁed by country and found that smoking was a signiﬁ-
cant predictor of less response to RTX in the Swedish study
group (OR = 0.24, 95% CI 0.07–0.89, p = 0.03) and there
was a trend in the register from the Czech Republic
(OR = 0.45, 95% CI 0.16–1.02, p = 0.06), while in the
other registers there was a trend towards a better response in
smokers (data not shown).
In a multivariate analysis including ACPA and other
known or potential predictors using a stepwise backward
selection, only the following two characteristics were sig-
niﬁcant predictors of good response: a lower number of prior
bDMARDs (OR = 0.63, 95% CI 0.44–0.91, p = 0.01) and
ACPA positivity (OR = 2.34, 95% CI 1.47–3.75,
p < 0.0001). In a different multivariate model with RF (but
without ACPA), RF positivity (OR = 1.44, 95% CI 1.01–
2.05, p = 0.04), lower baseline DAS28 (OR = 0.85, 95% CI
0.77–0.94, p = 0.002), and no concomitant glucocorticoids at
baseline (OR = 0.70, 95% CI 0.53–0.92, p = 0.01) were
independent predictors of EULAR good response at
6 months.
Longitudinal analyses of response by smoking
During the ﬁrst 6 months from baseline, 2958 and 822
follow-up visits were recorded for non-smokers and
Table 2. Effectiveness of rituximab treatment at 6 months in non-smokers and smokers.
Difference between groups
Non-smokers
(N = 1953)
Smokers
(N = 528) Crude p-value Adjusted p-value*
DAS28 6 months 4.2 ± 1.4 (1552) 4.0 ± 1.4 (394) 0.02
ΔDAS28 6 months −1.7 ± 1.6 (1516) −1.5 ± 1.6 (382) 0.006 0.44
EULAR response 6 months [1360] [308] 0.95
Good 19.6% 20.1%
Moderate 53.9% 52.9%
No 26.5% 26.9%
Remission/LDA 6 months 24.1% [1552] 28.2% [394] 0.10
The numbers in square brackets represent the total number of patients with available information.
DAS28, Disease Activity Score based on 28-joint count; EULAR, European League Against Rheumatism; LDA, low disease activity.
*Adjusted analyses were conducted only when the crude p value was < 0.05.
Table 3. Effectiveness of rituximab treatment at 6 months in non-smokers and smokers stratiﬁed by anti-citrullinated protein
antibody (ACPA) and rheumatoid factor (RF) status.
ACPA positive ACPA negative RF positive RF negative
Non-
smokers Smokers
Non-
smokers Smokers
Non-
smokers Smokers
Non-
smokers Smokers
EULAR response 6 months [524] [187] [151] [33] [986] [242] [261] [52]
Good 26.5% 21.9% 13.9% 6.1% 19.9% 21.9% 17.6% 11.5%
Moderate 47.7% 49.2% 51.0% 57.6% 54.5% 51.2% 52.1% 57.7%
No 25.8% 28.9% 35.1% 36.4% 25.7% 26.9% 30.3% 30.8%
Remission/LDA months 29.4% 27.6% 22.3% 15.8% 24.8% 30.6%
(p = 0.04)
22.0% 17.5%
The numbers in square brackets represent the total number of patients with available information. Analyses are unadjusted.
EULAR, European League Against Rheumatism; LDA, low disease activity.
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smokers, respectively. In the mixed-model analyses with
ΔDAS28 as the dependent variable, time (1/time) and smok-
ing status as ﬁxed factors, and country and individual patient
as random factors, the interaction between smoking and time
was not statistically signiﬁcant (p = 0.22) (Figure 1). Esti-
mated marginal means for non-smokers and smokers were
−1.69 (95% CI −1.76; −1.61) and −1.42 (95% CI −1.57;
−1.26), respectively (p = 0.002). However, the difference
disappeared when the model was adjusted for baseline dif-
ferences between smokers and non-smokers. In the ﬁnal
model, higher baseline DAS28 (p < 0.0001), male gender
(p = 0.02), RF positivity (p = 0.05), and lower number of
prior bDMARDs (p < 0.0001) were signiﬁcantly associated
with ΔDAS28 during this period. Smoking was not signiﬁ-
cant (p = 0.36). Estimated marginal means for non-smokers
and smokers were −1.60 (95% CI −1.69; −1.50) and −1.58
(95% CI −1.72; −1.44), respectively (p = 0.83). The same
analysis was performed with ACPA instead of RF, with
similar results. No signs of effect modiﬁcation of RF or
ACPA were found in the mixed-model analyses stratiﬁed
according to RF and ACPA status (data not shown).
Discussion
In this large, prospective, real-life cohort from several
European countries, smoking was not associated with
response to treatment with RTX in RA patients overall,
and only marginal differences were observed in sub-
groups. This is in contrast to what has been shown for
TNFi and even csDMARDs (methotrexate and combina-
tion therapies), the effectiveness of which is negatively
correlated with current smoking (4–6). However, it was
also evident that smokers differed from non-smokers,
since they had shorter disease duration and lower disease
activity at the start of treatment, and had tested more
treatments before, indicating a more severe disease
course, in accordance with numerous previous studies
on smoking and long-term outcome in RA (4, 17–19).
In a letter published by Khan et al with 150 patients, non-
smoking was strongly associated with response to RTX, in
addition to RF positivity, ACPA positivity, and baseline
DAS28 (16). Non-smokers had very high response rates
(≥ 98%) to RTX irrespective of their RF/ACPA status,
while current and previous smokers only achieved response
rates of ≥ 50% if they were seropositive. This was, however,
a small study, and the deﬁnition of response was a decrease
in DAS28 of ≥ 1.2 after 6 months of treatment in patients
with initial DAS28 scores > 5.1. There have been no other
studies conﬁrming these ﬁndings. In our study, we could not
differentiate between the response of smokers and non-
Table 4. Predictors of European League Against Rheumatism (EULAR) good response at 6 months.
Independent variable OR (95% CI) p
Smoking (smokers vs non-smokers) 1.04 (0.76–1.41) 0.82
Gender (male vs female) 1.33 (0.98–1.80) 0.07
Age (per year increase) 1.00 (0.99–1.01) 0.83
RA disease duration (per year increase) 0.99 (0.97–1.00) 0.13
Prior csDMARDs (number) 0.93 (0.85–1.02) 0.13
Prior bDMARDs (0–1 vs > 1) 0.85 (0.61–1.16) 0.30
RF (positive vs negative) 1.28 (0.92–1.77) 0.15
ACPA (positive vs negative) 2.37 (1.49–3.79) < 0.0001
Baseline DAS28 (per unit increase) 0.87 (0.79–0.96) 0.004
Baseline HAQ (per unit increase) 0.79 (0.65–0.95) 0.01
Concomitant GCs (yes vs no) 0.65 (0.51–0.84) 0.001
Concomitant csDMARDs (yes vs no) 1.02 (0.74–1.41) 0.89
RA, rheumatoid arthritis; csDMARDs, conventional synthetic disease-modifying anti-rheumatic drugs; bDMARDs, biological disease-
modifying anti-rheumatic drugs; RF, rheumatoid factor; ACPA, anti-citrullinated protein antibodies; DAS28, Disease Activity Score
based on 28-joint count; HAQ, Health Assessment Questionnaire; GC, glucocorticoids; OR, odds ratio; CI, conﬁdence interval.
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Figure 1. Unadjusted ﬁxed predicted change in 28-joint Disease Activ-
ity Score for smokers and non-smokers (mixed-model analysis).
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smokers, and there was no sign of effect modiﬁcation by RF
and ACPA status (Table 2).
A 2015 study, published in abstract form, examined the
relationship of smoking and response to tocilizumab, an anti-
interleukin-6 receptor monoclonal antibody (7). These pre-
liminary results indicate no negative effect of smoking on
clinical response. This discrepancy between smoking and
different bDMARDs, TNFi and non-TNFi bDMARDs may
imply different mechanisms behind the negative association
with smoking. There is increasing evidence that the devel-
opment of neutralizing anti-drug antibodies may be the
reason for inefﬁcacy (especially secondary inefﬁcacy or
loss of efﬁcacy) in a signiﬁcant number of patients treated
with TNFis, especially inﬂiximab and adalimumab (20).
There is, to date, no evidence for such a mechanism for
RTXor tocilizumab. In a 2014 study fromSweden, smoking
was associatedwith an increased risk of development of anti-
natalizumab antibodies in patients with multiple sclerosis
(21). Thus, anti-drug antibody formation could be one expla-
nation for the discrepancy observed between the effect of
smoking habits on response to TNFi and non-TNFi
bDMARDs and the evidence that exists today. However,
this is only a hypothesis and remains to be further studied.
Another point that has to be taken into consideration is the
major discrepancies observed across countries. In this study,
smoking was a negative predictor of good response to RTX
treatment in the Swedish cohort and a similar trend was
observed in the cohort from the Czech Republic, but no
signiﬁcant association was observed in any other registers.
There is a need for multicentre, international, prospective
studies with both TNFis and non-TNFi-bDMARDs, to
examine the real association between smoking and clinical
response regardless of potential confounders, such as coun-
try and cultural differences across nations.
This study conﬁrmed previous results regarding the
positive predictive value for good response to RTX treat-
ment of ACPA positivity, lower number of prior
bDMARDs, and absence of concomitant glucocorticoids
(13). Since ACPA is also associated with smoking (1), it is
an important confounder to take into consideration when
examining response to RTX treatment, including it in the
multivariate analyses. To account for effect modiﬁcation,
stratiﬁed analyses by ACPA (and by RF) status were
performed. Smoking was not associated with response to
RTX, in either ACPA-positive or ACPA-negative patients.
This study has several limitations that need to be
addressed. It is an observational study, and the risk of resi-
dual confounding even after correction for potential con-
founders is present. Information about smoking status was
available for a subset of patients and was collected at base-
line, that is, treatment start for all countries but Sweden,
where the information was available at diagnosis. Since a
strong association was observed in the Swedish subset only,
one plausible explanation for the discrepancy is that smoking
cessation occurring after diagnosis but before starting RTX
could inﬂuence the ﬁndings, since we could not look sepa-
rately at never and past smokers. We do not know what
happened during the observational period, for example
whether some patients changed their smoking habits,
although if that happened it would most likely be for a
minority of patients, as we know from clinical practice and
previous studies (22). This is a multinational cohort, and
signiﬁcant heterogeneity is found across countries. We
tried to account for this by including country as a random
variable in the mixed-effect model analyses, as well as
performing sensitivity analyses stratiﬁed by country. Miss-
ing data is a common problem with observational studies.
We used LOCF for DAS28 in cases of missing DAS28 in
patients who had a follow-up visit. We also used mixed-
model analyses, which handle missing data. The lack of
radiological data is also a limitation.
However, signiﬁcant strengths of this study are the
large number of patients, which provides enough power
to detect potential differences between groups and to
adjust for potential confounders; the real-life nature of
the data, which increases the external validity of the
results; and the fact that countries with cultural differ-
ences and different treatment protocols provided data.
Conclusion
Current smoking habits had very limited impact on disease
activity and response to RTX in this large, observational,
multinational RA cohort. However, smokers had several
baseline characteristics indicating more severe disease,
such as more previous treatments tested, despite shorter
disease duration, and a lower baseline disease activity, pos-
sibly indicating other reasons for treatment start, such as a
radiographic progression, about which we did not have
information. Thus, a validation study in a trial-based setting
iswarranted.Althoughourﬁndings do not support the notion
that smoking cessation will increase the likelihood of
response to RTX, it should be stressed that RA patients
have many other reasons to quit smoking, for example to
reduce their risks of a more destructive disease course, extra-
articular manifestations, and cardiovascular comorbidities.
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